471 related articles for article (PubMed ID: 32083962)
1. Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease.
Scheen AJ
Expert Opin Drug Saf; 2020 Mar; 19(3):243-256. PubMed ID: 32083962
[No Abstract] [Full Text] [Related]
2. The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: A systematic review and meta-analysis.
Wang C; Zhou Y; Kong Z; Wang X; Lv W; Geng Z; Wang Y
Diabetes Obes Metab; 2019 Apr; 21(4):1018-1026. PubMed ID: 30565382
[TBL] [Abstract][Full Text] [Related]
3. Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.
Scheen AJ
Diabetes Metab; 2019 Apr; 45(2):110-121. PubMed ID: 30477733
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic/Pharmacodynamic Properties and Clinical Use of SGLT2 Inhibitors in Non-Asian and Asian Patients with Type 2 Diabetes and Chronic Kidney Disease.
Scheen AJ
Clin Pharmacokinet; 2020 Aug; 59(8):981-994. PubMed ID: 32201911
[TBL] [Abstract][Full Text] [Related]
5. Sodium-glucose cotransporter 2 inhibitors in type 2 diabetes patients with renal function impairment slow the annual renal function decline, in a real clinical practice.
Hirai T; Kitada M; Monno I; Oda E; Hayashi Y; Shimada K; Takagaki Y; Ogura Y; Fujii M; Konishi K; Sakurai M; Nakagawa A; Koya D
J Diabetes Investig; 2021 Sep; 12(9):1577-1585. PubMed ID: 33417741
[TBL] [Abstract][Full Text] [Related]
6. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V
Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905
[TBL] [Abstract][Full Text] [Related]
7. SGLT2 inhibition and kidney protection.
Nespoux J; Vallon V
Clin Sci (Lond); 2018 Jun; 132(12):1329-1339. PubMed ID: 29954951
[TBL] [Abstract][Full Text] [Related]
8. An update on the safety of SGLT2 inhibitors.
Scheen AJ
Expert Opin Drug Saf; 2019 Apr; 18(4):295-311. PubMed ID: 30933547
[TBL] [Abstract][Full Text] [Related]
9. Association Between SGLT2 Inhibitors vs DPP4 Inhibitors and Renal Outcomes Among Patients With Type 2 Diabetes.
Au PCM; Tan KCB; Cheung BMY; Wong ICK; Li HL; Cheung CL
J Clin Endocrinol Metab; 2022 Jun; 107(7):e2962-e2970. PubMed ID: 35303075
[TBL] [Abstract][Full Text] [Related]
10. SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence.
Davidson JA
Postgrad Med; 2019 May; 131(4):251-260. PubMed ID: 30929540
[TBL] [Abstract][Full Text] [Related]
11. [SGLT2 inhibitors: focus on kidneys and nephroprotection].
Scheen AJ; Delanaye P
Rev Med Suisse; 2021 Aug; 17(747):1397-1403. PubMed ID: 34431632
[TBL] [Abstract][Full Text] [Related]
12. Understanding the protective effects of SGLT2 inhibitors in type 2 diabetes patients with chronic kidney disease.
Scheen AJ; Delanaye P
Expert Rev Endocrinol Metab; 2022 Jan; 17(1):35-46. PubMed ID: 34908510
[TBL] [Abstract][Full Text] [Related]
13. SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
[TBL] [Abstract][Full Text] [Related]
14. The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium-glucose cotransporter-2 inhibitor, in type 2 diabetes.
Jeong SI; Ban MS; Hwang JG; Park MK; Lim S; Kim S; Kwon SK; Kim Y; Cho JM; Na JJ; Huh W; Chung JY
Diabetes Obes Metab; 2024 Jul; 26(7):2588-2597. PubMed ID: 38618974
[TBL] [Abstract][Full Text] [Related]
15. [SGLT2 inhibitors in patients with chronic kidney disease : from clinical trials to guidelines and new prospects for clinical practice].
Scheen AJ; Delanaye P
Rev Med Liege; 2021 Mar; 76(3):186-194. PubMed ID: 33682388
[TBL] [Abstract][Full Text] [Related]
16. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.
Mima A
J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432
[TBL] [Abstract][Full Text] [Related]
17. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.
Alicic RZ; Johnson EJ; Tuttle KR
Am J Kidney Dis; 2018 Aug; 72(2):267-277. PubMed ID: 29866460
[TBL] [Abstract][Full Text] [Related]
18. Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial.
Tanaka A; Shimabukuro M; Okada Y; Sugimoto K; Kurozumi A; Torimoto K; Hirai H; Node K;
Cardiovasc Diabetol; 2020 Jun; 19(1):85. PubMed ID: 32534578
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease.
Kelly MS; Lewis J; Huntsberry AM; Dea L; Portillo I
Postgrad Med; 2019 Jan; 131(1):31-42. PubMed ID: 30449220
[TBL] [Abstract][Full Text] [Related]
20. Kidney outcomes of SGLT2 inhibitors among older patients with diabetic kidney disease in real-world clinical practice: the Japan Chronic Kidney Disease Database Ex.
Kitaoka K; Yano Y; Nagasu H; Kanegae H; Chishima N; Akiyama H; Tamura K; Kashihara N
BMJ Open Diabetes Res Care; 2024 May; 12(3):. PubMed ID: 38816204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]